Defensive · 52 dossiers

Private-wireless 900 MHz spectrum re-rating that converted from FCC policy to a first full-year GAAP profit ($18.52M) and an activated buyback; the 6→10 MHz catalyst is banked and price is extended at fresh highs, so the next leg rides…

Managed-care margin recovery off the 2025 ACA blowup is largely priced (+137% off the $25.08 low into the low-$60s). The fresher driver is 2027 repricing ~14% ACA rate-hike filings (WSJ 2026-07-08) signal a hot medical-cost trend that…

AI-underwriting neobank re-accelerating as the sell-side chases the June breakout Benchmark to $475 (7/1), Citizens to $450 (7/9) after the ATH at $318.66. Q1 rev +47% to $158.4M on a record-low 1.69% past-due; the Coastal bank-funding…

Butterfly Embedded chip-licensing story got marquee validation Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 a maturing,…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue)…

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)…

The Iran-war crude premium has fully unwound: WTI crude ~$69 (Jul 2) vs $100+ in May after the June 17 US–Iran MOU reopened Hormuz, and W&T which never rallied on the spike has broken its $4 shelf to $3.11 (Jul 1). A hedged,…

Q2 (07-16) missed at $2.12 vs $2.25 and management cut the FY alumina outlook on Pinjarra refinery problems five sell-side target cuts in nine sessions (BMO $55, JPM $52, WF $71), zero raises. The Hormuz premium is gone, the next catalyst…

Edge-AI silicon small-cap whose 2026-05-12 Q1 beat + Q2 guide-raise drove a parabolic to an $85.77 ATH (May 26), then a -12.4% distribution day (Jun 5). Catalyst is spent, no binary lands until the ~Aug Q2 print, and price sits above the…

The cyclical-bottom trade has unwound: after a $90.16 June high, ATKR trades ~$72.68, below its $78.03 50-day and pressing the $69.69 200-day, with RBC cutting its target to $76 (7/16) and Wall Street Zen going to Hold (7/18). The…

Driverless-freight commercialization keeps widening (McLane Dallas–Houston live, ~10 Sun Belt lanes, 200+ truck year-end target), but the tape is rangebound: a 2026-07-01 +9% spike to $7.45 on Craig-Hallum's $18 call and a clean safety…

TAVR disruptor whose de-risking catalysts (CMS CED 4/28, first US patients 5/5, French ANSM clearance 6/8) are now exhausted; price ran to a fresh ~$11.06 high then faded to $9.77 (7/10) on no news, back near the in-the-money $250M ATM…

Post-miss +46% V-recovery has rolled over ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Broken protein-staple turnaround; the June–July bounce off the $7.82 low is oversold mean-reversion, not re-acceleration. A new CEO effective July 29 and Stephens' $20 PT are scaffolding the ~Aug 3 Q3 print is the binary that validates or…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Freight-cycle inflection play where the sell-side is finally re-rating: Stephens (07-08) and Citizens (07-15) both initiated at $60, roughly double the stale $33-35 consensus. But Q1 margins moved the wrong way, insiders sold the whole…

Phase 3 depression win for DT120 already ran +60% in public; a seven-shop $50–$74 target band and a $700M raise at $34 are digested, not fresh. Post-catalyst name maturing under a dilution overhang the entry is a base that holds $34, not…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-the published invalidation levels still under the 200-EMA and the…

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped accelerating in mid-May and now drifts through an empty window into the ~August Q2 print the…

Matured auto/home insurance lead-gen cyclical that re-rated on the tape: a +6.91% breakout on 2026-06-26 (~4x average volume) reclaimed the declined ~$20.30 200-DMA, confirmed by a live estimate-revision cycle (Zacks consensus EPS +21% in…

Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217% above…

Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the…

Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the…

AI-chip specialty/photonics differentiated vs TSM (not a dup), but Mubadala $1.91B block overhang caps upside until absorbed; clean entry is a 52w-high reclaim post-block, not now.

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Insider-cluster leg has already paid: Malone/Fries/Nair bought the post-distribution $4.98 June base, and the common is $7.34 ~47% higher in under a month. July brought Citi's downgrade to Neutral (PT $8) and a Barclays Underweight at…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

Deli prepared-foods roll-up keeps compounding Q1 FY2027 (2026-06-08) revenue +49.7% YoY but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

Cruise complex re-rating on the fuel-cost collapse from the 2026-06-15 U.S.–Iran peace deal; NCLH is the highest-torque, most-levered name. Sell-side has now clustered ($22–25 PTs: Citi, Wells Fargo, TD Cowen), signaling the theme is…

AI-native private-flood MGA disrupting the federal NFIP; a rare profitable insurtech (57% adj-EBITDA margin) but revenue growth is decelerating 34%→29% and the sell-side is already fully engaged, with consensus PT $31.23 sitting at/below…

Post-lockup washout in a 28%-growth SASE/SSE leader: NTSK trades ~$12.78, ~45% below its $23 debut, at roughly 3x EV/S while ARR compounds 29%. The mispricing is real, but the chart is broken below the 200-day a base-and-reclaim candidate,…

Freight-cycle recovery led by the top-margin LTL name is now drawing its first upgrades into strength (Evercore to Outperform $237, Jul 1; Goldman Buy $235, Jun 23), but growth is still fuel+price with tons/day -3.8%, targets sit at spot…

Travel-reopening laggard flipped to a live re-rate: PEB broke its mid-teens base to a 52-week high ($19.75) as three desks lifted targets Truist to $22 (2026-06-29) off its first roadshow since 2019. The discount-to-NAV gap has largely…

Travel-leisure-reopening (ACCELERATING since 2026-06-17) already re-rated PK ~40% off spring lows to ~$14.42, pressing the 52-wk high $14.95 and the $14.16 avg consensus PT. Q1 FFO $0.45 beat $0.39; FY26 guide $1.74–$1.90. The laggard has…

Merger spread, not a story: SWKS collapsed ~25% on Apple iPhone content loss, dragging implied deal value ($32.50 + 0.960 SWKS) from ~$102 to ~$87.7 while QRVO sits $85.50 under 3% left for underwriting a China SAMR Phase II review with no…

Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken…

Oral-GPCR platform narrative has matured from accelerating to extended after a ~3.5x run to an all-time high of $37.99; the ENDO 2026 visibility event came and went and the tape now sits in a catalyst vacuum, with the first real binary…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

SI-joint-fusion grower adding a Smith+Nephew pelvic-trauma distribution leg; tape has firmed from broken to basing and is now testing the ~$17 200-day resistance shelf. Still a mid-teens grower (+11.2% Q1), not hypergrowth the ~2026-08-03…

Specialty E&S compounder printing 20%+ operating ROE with Apollo's Lloyd's platform now integrated; the low-$40s-to-highs re-rate is a MATURING move that ran to RSI ~89 into late June. Next real binary is the Aug 4 Q2 print a fresh chase…

Freight-cycle recovery is accelerating national truckload spot at a cycle-high ~$2.82/mi and tender rejections ~13% (a 4-year high) but SNDR rolled ~7% off its $38.66 June high to ~$35.80 while its own P&L (Q1 adj EPS $0.13, ops income…

Space-launch-satellite theme re-accelerated into July (07-06), yet Spire trades as its smallest, highest-beta laggard. Live legs: a European defense pivot (Diehl Defence MoU 06-10, Munich 100-sat/yr line) and residual SpaceX-IPO proxy flow…

Busted-IPO thrift retailer grinding a base on consumer trade-down plus a June 2 debt-cost cut; the June 27 Russell index deletion pulled the passive bid and capped the bounce near $10, and no hard catalyst lands until the ~Aug 7 Q2 print.…

Quality home-furnishings compounder riding the consumer-discretionary rotation; Q1 (2026-05-21) reaccelerated every brand to positive comp and the sell-side is catching up (Evercore→$230 6/23, B of A $250 6/12). But near $226 the tape sits…